bpc-157 and tb-500 oral / for Women Oral vs Injectable BPC-157: Differences,

Avoid using GLP-1 RAs if you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome (Multiple endocrine neoplasia type 2 syndrome)

Overall survival (OS) was increased to 74% by decreasing the dose of cyclophosphamide to below 200 mg/kg, but the probability of graft rejection (GR) remained high (35%) and event-free survival (EFS) remained low (49%) [80], probably due to inadequate immunosuppression and/or a failure to eradicate the massive erythroid hyperplasia

The published benefit figures are 95 percent for gut healing and repair support, 92 percent for reduction in inflammation, 90 percent for immune system support and 88 percent for improved digestion and gut integrity

Invest in ME has done so for 15 years, and each year I watch with interest as they often include European researchers who are not a part of North American collaboratives